TWI764951B - 用於處理疼痛之右美托咪啶經皮遞送裝置 - Google Patents

用於處理疼痛之右美托咪啶經皮遞送裝置 Download PDF

Info

Publication number
TWI764951B
TWI764951B TW106137654A TW106137654A TWI764951B TW I764951 B TWI764951 B TW I764951B TW 106137654 A TW106137654 A TW 106137654A TW 106137654 A TW106137654 A TW 106137654A TW I764951 B TWI764951 B TW I764951B
Authority
TW
Taiwan
Prior art keywords
dexmedetomidine
hours
delivery device
transdermal delivery
individual
Prior art date
Application number
TW106137654A
Other languages
English (en)
Chinese (zh)
Other versions
TW201817419A (zh
Inventor
首藤十太郎
皖寧 宋
蘿絲 剛薩爾維斯
希平 黃
Original Assignee
美商帝國製藥美國股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商帝國製藥美國股份有限公司 filed Critical 美商帝國製藥美國股份有限公司
Publication of TW201817419A publication Critical patent/TW201817419A/zh
Application granted granted Critical
Publication of TWI764951B publication Critical patent/TWI764951B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106137654A 2016-10-31 2017-10-31 用於處理疼痛之右美托咪啶經皮遞送裝置 TWI764951B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662415248P 2016-10-31 2016-10-31
US62/415,248 2016-10-31
US201762547582P 2017-08-18 2017-08-18
US62/547,582 2017-08-18

Publications (2)

Publication Number Publication Date
TW201817419A TW201817419A (zh) 2018-05-16
TWI764951B true TWI764951B (zh) 2022-05-21

Family

ID=62020311

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106137654A TWI764951B (zh) 2016-10-31 2017-10-31 用於處理疼痛之右美托咪啶經皮遞送裝置

Country Status (10)

Country Link
US (1) US12527770B2 (https=)
EP (1) EP3532038A4 (https=)
JP (3) JP2019534288A (https=)
KR (4) KR20250105683A (https=)
CN (2) CN110022865A (https=)
BR (1) BR112019006955A2 (https=)
CA (1) CA3038354C (https=)
RU (1) RU2723761C1 (https=)
TW (1) TWI764951B (https=)
WO (1) WO2018081812A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
CN115813888A (zh) 2016-12-20 2023-03-21 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
EP3558276B1 (en) 2016-12-20 2024-11-06 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
IL267689B2 (en) 2016-12-31 2025-05-01 Bioxcel Therapeutics Inc Use of sublingual dexmedetomidine for the treatment of agitation
US12329862B2 (en) * 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
BR112020026672A2 (pt) 2018-06-27 2021-03-30 Bioxcel Therapeutics, Inc. Formulações de filme contendo dexmedetomidina e métodos para produzi-las
CA3135552C (en) * 2019-04-17 2023-09-26 Lts Lohmann Therapie-Systeme Ag Ketamine containing transdermal therapeutic system comprising free hydroxyl groups
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
WO2021026380A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Phenyltriazole compounds for the treatment of pain
WO2021026375A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Fused bicyclic compounds for the treatment of pain
WO2021026377A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Lactam-containing compounds for the treatment of pain
WO2021026378A1 (en) * 2019-08-07 2021-02-11 Alkermes, Inc. Indole compounds for the treatment of pain
CN111281850A (zh) * 2020-03-14 2020-06-16 周琛 止痛药物组合物及其用途
CN116098876A (zh) * 2021-11-11 2023-05-12 北京泰德制药股份有限公司 一种右美托咪定透皮贴剂及其制备方法和应用
CN117582424A (zh) * 2022-08-17 2024-02-23 宜昌人福药业有限责任公司 右美托咪定经皮组合物、透皮贴剂及其制备方法和应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
TW202519210A (zh) * 2023-09-05 2025-05-16 美商帝國製藥美國有限公司 用於治療疼痛之經皮遞送貼片

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201526927A (zh) * 2013-10-07 2015-07-16 Teikoku Pharma Usa Inc 用於經皮輸送非鎮靜量右美托咪啶之方法及組成物

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2101114B (en) 1981-07-10 1985-05-22 Farmos Group Ltd Substituted imidazole derivatives and their preparation and use
JPS60163811A (ja) 1984-02-06 1985-08-26 Watanabe Yakuhin Kogyo Kk プロプラノロ−ル含有外用貼付剤
FI844786A0 (fi) 1984-12-04 1984-12-04 Farmos Oy Terapeutiskt utnyttjbar foerening.
FI864570A0 (fi) 1986-11-11 1986-11-11 Farmos Oy Terapeutiskt anvaendbar foerening.
GB2206880B (en) 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
GB2215206B (en) 1988-02-29 1991-07-03 Farmos Oy 4-substituted imidazole derivatives useful in perioperative care
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5217718A (en) 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
US5304569A (en) 1989-11-13 1994-04-19 Orion-Yhtyma Oy Compositions and their use in lowering intraocular pressure
US5070084A (en) 1990-02-26 1991-12-03 Campbell James N Treatment of sympathetically maintained pain
US5447947A (en) 1990-02-26 1995-09-05 Arc 1 Compositions and methods of treatment of sympathetically maintained pain
JP2849937B2 (ja) 1990-04-18 1999-01-27 日東電工株式会社 医療用貼付剤
GB9111732D0 (en) 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
AU2782592A (en) 1991-10-15 1993-05-21 Cygnus Therapeutic Systems Thermal enhancement of transdermal drug administration
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
GB2281206A (en) 1993-08-25 1995-03-01 Orion Yhtymae Oy Use of dexmedetomidine
JPH0776526A (ja) 1993-09-06 1995-03-20 Sansei Seiyaku Kk 乳酸エステルを含有する経皮吸収製剤
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
GB2290964A (en) 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
CA2198390C (en) 1994-09-14 2009-08-11 James E. Garbe Matrix for transdermal drug delivery
US5635203A (en) 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
CN1101825C (zh) 1995-03-31 2003-02-19 积水化学工业株式会社 制备溶剂型丙烯酸压敏粘合剂和医用压敏粘合剂的方法
CN1188189C (zh) 1995-06-07 2005-02-09 奥瑟－麦内尔制药公司 基质层含有17－脱乙酰基诺孕酯的经皮贴片及基质的用途
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
GB9521680D0 (en) 1995-10-23 1996-01-03 Orion Yhtymo Oy New use of imidazole derivatives
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
EP1021204B1 (en) 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US20020102291A1 (en) 1997-12-15 2002-08-01 Noven Pharmaceuticals, Inc. Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
US20020177592A1 (en) 1998-02-25 2002-11-28 Olney John W. Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects
US20020068754A1 (en) 1998-02-25 2002-06-06 Olney John W. Combination of adrenergic agonist and aryl-cyclo-alkanolamine for relieving chronic pain without adverse side effects
US20020016319A1 (en) 1998-02-25 2002-02-07 Olney John W. Combined adamantane derivative and adrenergic agonist for relief of chronic pain without adverse side effects
AR015744A1 (es) 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
MXPA01003310A (es) 1998-10-02 2003-05-15 3M Innovative Properties Co Sistema de suministro de farmaco originados en mucosa y aplicaciones animales.
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
EP1227807B1 (en) 1998-10-20 2005-03-30 Omeros Corporation Irrigation solution and method for inhibition of pain and inflammation
US20030170195A1 (en) 2000-01-10 2003-09-11 Noven Pharmaceuticals, Inc. Compositions and methods for drug delivery
PE20001396A1 (es) 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
DE19918106A1 (de) 1999-04-22 2000-10-26 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit neutralisierten Acrylathaftklebern
GB9913677D0 (en) 1999-06-11 1999-08-11 Imperial College Formulation
DE19938823A1 (de) 1999-08-19 2001-02-22 Boehringer Ingelheim Pharma Medikamentöse Behandlung des Restless Leg Syndroms
AU4904101A (en) 1999-12-08 2001-07-09 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
AU4341401A (en) 2000-03-10 2001-09-24 Durect Corp Opioid formulations
WO2001089448A2 (en) 2000-03-28 2001-11-29 Olney John W Combination of adrenergic agonist and nmda antagonist for relieving chronic pain without adverse side effects
US20050042194A1 (en) 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
EP1155617A1 (en) 2000-05-17 2001-11-21 Rockwool International A/S Mineral wool plant substrate
DE10138722C5 (de) 2000-08-17 2017-05-24 Schaeffler Technologies AG & Co. KG Antriebsstrang
US7635488B2 (en) 2001-03-13 2009-12-22 Dbv Technologies Patches and uses thereof
FR2822049B1 (fr) 2001-03-13 2003-08-01 Dbv Medica 1 Patch destine notamment a depister l'etat de sensibilisation d'un sujet a un allergene, procede de fabrication et utilisation
FR2832311B1 (fr) 2001-11-21 2004-04-16 Besins Int Belgique Poudre filmogene, compositions la comprenant, leurs procedes de preparation et leurs utilisations
AR033748A1 (es) * 2002-05-15 2004-01-07 Thalas Group Inc Un dispositivo para la administracion transdermica de sustancias farmacologicamente activas que comprende dos capas adhesivas superpuestas y un procedimiento para prepararlo
KR100511492B1 (ko) 2002-10-11 2005-08-31 주식회사 태평양 에페리손, 톨페리손 또는 그것들의 염을 포함하는경피흡수제제
HRP20050633A2 (en) 2003-01-23 2006-06-30 Shire Holdings Ag Formulation and methods for the treatment of thrombocythemia
DE10305137A1 (de) 2003-02-07 2004-08-26 Novosis Ag Transdermale therapeutische Abgabesysteme mit einem Butenolid
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050059664A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
TWI341735B (en) 2003-07-31 2011-05-11 Hisamitsu Pharmaceutical Co Adhesive preparations
WO2005034998A2 (en) 2003-09-12 2005-04-21 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050058696A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2542778C (en) 2003-10-28 2012-05-29 Noven Pharmaceuticals, Inc. Transdermal drug delivery composition
PT1761266E (pt) 2004-05-25 2013-06-04 Galderma Pharma Sa Compostos, formulações, e métodos para tratamento ou prevenção de distúrbios inflamatórios da pele
JP2008514612A (ja) 2004-09-23 2008-05-08 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
US20060166901A1 (en) 2005-01-03 2006-07-27 Yu Ruey J Compositions comprising O-acetylsalicyl derivatives of aminocarbohydrates and amino acids
US8114090B2 (en) 2005-01-06 2012-02-14 Kertzner Richard I Drill centering tool for removal of orthopedic plug
WO2006099541A2 (en) 2005-03-15 2006-09-21 Richard Daniel Carliss Therapeutic wound care product
US20070134310A1 (en) 2005-09-23 2007-06-14 Nedberge Diane E Transdermal risperidone delivery system
US8383149B2 (en) 2005-09-23 2013-02-26 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
JP5128483B2 (ja) 2005-10-24 2013-01-23 テイコク ファーマ ユーエスエー インコーポレーテッド Ｎ，２，３−トリメチル−２−イソプロピルブタナミドの局所用疼痛緩和組成物並びにその使用法
TWI389709B (zh) 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN1994290B (zh) 2006-01-04 2011-03-16 上海医药工业研究院 卡巴拉汀透皮贴剂及其制备方法
CN101395164A (zh) 2006-01-10 2009-03-25 罗伊·J·于 N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法
RU2008130448A (ru) 2006-01-27 2010-03-10 Ф. Хоффманн-Ля Рош Аг (Ch) Применение производных 4-имидазола для расстройств цнс
JP2009528289A (ja) 2006-02-27 2009-08-06 ミシャロウ、アレクサンダー 対抗適応を誘発することにより神経伝達物質系を調節する方法
CA2644311C (en) 2006-03-01 2012-07-10 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
GB0611241D0 (en) 2006-06-07 2006-07-19 Daniolabs Ltd The treatment of increased sebum production
EP2062575B1 (en) 2006-09-11 2012-02-15 Sekisui Chemical Co., Ltd. Adhesive preparation comprising desglymidodrine
US20090098191A1 (en) 2007-10-16 2009-04-16 Anderson Christopher G Use of bases to stabilize transdermal formulations
US8114898B2 (en) 2007-11-16 2012-02-14 Allergan, Inc. Compositions and methods for treating purpura
US8011146B2 (en) 2007-12-19 2011-09-06 William Krause Blast-proof window and mullion system
WO2009124755A1 (en) 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
EP2286814B1 (en) 2008-05-15 2013-10-16 Hisamitsu Pharmaceutical Co., Inc. Transdermal preparation containing palonosetron
US20110223204A1 (en) 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
WO2010014076A1 (en) 2008-07-28 2010-02-04 EndogenX, Inc. Methods to treat pain using an alpha-2 adrenergic agonist and an endothelin antagonist
US20100202979A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20120156244A1 (en) 2008-08-01 2012-06-21 Alpha Synergy Development Inc. Nasal Compositions and Uses Thereof
US20100197694A1 (en) 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20110244058A1 (en) 2008-08-01 2011-10-06 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20110257188A1 (en) 2008-08-01 2011-10-20 Gerald Horn Compositions and methods for the treatment of nasal conditions
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
US9308203B2 (en) 2008-10-01 2016-04-12 Taiwan Biotech Co., Ltd. Pressure sensitive adhesive matrix device or system for the treatment or prevention of onychomycosis or tinea pedis
US8603497B2 (en) 2008-10-30 2013-12-10 National University Corporation Okayama University Composition for local anesthesia
EP2376073A2 (en) 2008-11-30 2011-10-19 Oron Zachar Dermal application of vasoconstrictors
US20120095104A1 (en) 2008-11-30 2012-04-19 Oron Zachar Use of vasoconstrictors
US20100196286A1 (en) 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
FR2942138A1 (fr) 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
JP2012158521A (ja) 2009-04-17 2012-08-23 Kureha Corp 外用剤
SG175979A1 (en) 2009-05-15 2011-12-29 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
WO2011070069A1 (en) 2009-12-09 2011-06-16 I-Tech Ab Process for preparation of medetomidine
US20130072532A1 (en) * 2010-01-08 2013-03-21 Recro Pharma, Inc. Topical transdermal dexmedetomidine compositions and methods of use thereof
US9327105B2 (en) 2010-03-26 2016-05-03 Itrace Biomedical Inc. Active transdermal drug delivery system and the method thereof
EP2558101A4 (en) 2010-04-15 2013-09-18 Univ Mcgill TOPICAL TREATMENTS OF PAIN
US9023788B2 (en) 2010-04-20 2015-05-05 New York University Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
US8563031B2 (en) 2010-05-27 2013-10-22 Absize, Inc. Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
AU2011331511C1 (en) 2010-11-17 2018-01-18 Hexal Ag Transdermal therapeutic system comprising buprenorphine
TWI433904B (zh) 2011-01-12 2014-04-11 Taiwan Biotech Co Ltd 多奈哌齊經皮貼片
US20120202864A1 (en) 2011-02-03 2012-08-09 Alpha Synergy Development Inc. Compositions and Methods for Treatment of Glaucoma
US20120309720A1 (en) 2011-02-03 2012-12-06 Alpha Synergy Development Inc. Compositions and methods for treatment of glaucoma
CA2833474C (en) 2011-04-18 2017-09-19 Hisamitsu Pharmaceutical Co., Inc. Method for producing patch, and patch
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
JP2014530847A (ja) 2011-10-19 2014-11-20 ガルデルマ ソシエテ アノニム 毛細血管腫の治療方法
WO2013072763A2 (en) 2011-11-16 2013-05-23 Nometics Inc. Non-sensitizing transdermal clonidine patch
WO2013090278A2 (en) 2011-12-11 2013-06-20 Recro Pharma, Inc. Intranasal dexmedetomidine compositions and methods of use thereof
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
HUE035312T2 (en) 2012-01-31 2018-05-02 Gruenenthal Gmbh Pharmaceutical patch (1R, 4R) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano [3,4- b] for transdermal administration of indole] -4-amine
WO2013173317A1 (en) 2012-05-14 2013-11-21 Prospire, Llc TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS
CN110354267A (zh) 2012-08-31 2019-10-22 法尔麦兹公司 用于低血压复苏的方法和组合物
US20150366821A1 (en) 2012-11-13 2015-12-24 Ucl Business Plc Adrenergic agonists for use in treating liver damage
WO2014105480A1 (en) 2012-12-28 2014-07-03 Teikoku Pharma Usa, Inc. Extended buprenorphine transdermal delivery compositions and methods for using the same
KR101881791B1 (ko) 2013-10-07 2018-07-25 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정성 덱스메데토미딘 경피 조성물을 사용하여 금단 증후군을 치료하기 위한 방법 및 조성물
KR101948779B1 (ko) * 2013-10-07 2019-05-21 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
CA2924233C (en) 2013-10-07 2018-10-23 Teikoku Pharma Usa, Inc. Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions
US20150098982A1 (en) * 2013-10-07 2015-04-09 Teikoku Pharma Usa, Inc. Methods and Compositions for Managing Pain Comprising Dexmedetomidine Transdermal Compositions
US9974754B2 (en) 2013-12-18 2018-05-22 Maruishi Pharmaceutical Co., Ltd. Hydrous adhesive patch
WO2016105449A1 (en) 2014-12-22 2016-06-30 Seth Lederman Compounds for use as pain therapeutics
BR112019006955A2 (pt) 2016-10-31 2019-07-02 Teikoku Pharma Usa Inc métodos de controle da dor usando dispositivos de distribuição transdérmica de dexmedetomidina
TWI772807B (zh) 2019-05-27 2022-08-01 日商救急藥品工業股份有限公司 外用製劑
KR20240027808A (ko) 2021-08-23 2024-03-04 이창 휴먼웰 파마슈티칼 코포레이션, 리미티드 덱스메데토미딘 경피 조성물, 투피 패치 및 그 제조 방법과 응용
CN116098876A (zh) 2021-11-11 2023-05-12 北京泰德制药股份有限公司 一种右美托咪定透皮贴剂及其制备方法和应用
TW202519210A (zh) 2023-09-05 2025-05-16 美商帝國製藥美國有限公司 用於治療疼痛之經皮遞送貼片

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201526927A (zh) * 2013-10-07 2015-07-16 Teikoku Pharma Usa Inc 用於經皮輸送非鎮靜量右美托咪啶之方法及組成物

Also Published As

Publication number Publication date
WO2018081812A2 (en) 2018-05-03
KR20210113439A (ko) 2021-09-15
EP3532038A2 (en) 2019-09-04
JP2023036825A (ja) 2023-03-14
RU2723761C1 (ru) 2020-06-17
CA3038354C (en) 2021-08-17
TW201817419A (zh) 2018-05-16
CA3038354A1 (en) 2018-05-03
BR112019006955A2 (pt) 2019-07-02
JP2019534288A (ja) 2019-11-28
CN110022865A (zh) 2019-07-16
JP2025108704A (ja) 2025-07-23
KR20230048156A (ko) 2023-04-10
US20180117012A1 (en) 2018-05-03
WO2018081812A3 (en) 2019-01-17
US12527770B2 (en) 2026-01-20
EP3532038A4 (en) 2020-06-03
KR20190060007A (ko) 2019-05-31
CN121868263A (zh) 2026-04-17
KR20250105683A (ko) 2025-07-08

Similar Documents

Publication Publication Date Title
TWI764951B (zh) 用於處理疼痛之右美托咪啶經皮遞送裝置
CN105682650B (zh) 用于使用非镇静性右旋美托咪啶经皮组合物治疗戒断综合征的方法和组合物
JP4316800B2 (ja) メチルフェニデートで注意欠乏障害及び注意欠乏／活動亢進障害を治療する組成物及び方法
KR101891186B1 (ko) 덱스메데토미딘 경피 조성물을 포함하는 통증을 관리하기 위한 방법 및 조성물
US20250275930A1 (en) Transdermal delivery patch for treating pain
CN111447927A (zh) 纳洛酮经皮给药装置及其使用方法
US20040228906A1 (en) Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
HK40010492A (en) Methods of managing pain using dexmedetomidine transdermal delivery devices
EP1323421A1 (en) Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
JP2018528175A (ja) 経皮送達系
BR112016006200B1 (pt) Uso de dispositivo de distribuição transdérmica para tratar síndrome de abstinência